Daniela Lucas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniela Lucas has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Jose Munoz
Department of Bioengineering, University of California San Diego, La Jolla, CA
9 shared publications - Pedro Cabrales
University of California San Diego
9 shared publications - Andre Francis Palmer
The Ohio State University
6 shared publications Andre F. Palmer
5 shared publications- Quintin O'BOyle
The Ohio State University
4 shared publications Carlos Munoz
3 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Elsevier in SSRN Electronic Journal
Molecular Size-Dependent Effects of Polymerized Hemoglobin on Blood Rheology and Microvascular Perfusion
Background: Hemoglobin-based oxygen carriers (HBOCs) could provide an alternative to blood transfusion when donor blood is unavailable, but clinical translation has been limited by vasoactivity and impaired microvascular perfusion. We investigated how polymerized hemoglobin (PolyhHb) molecular size influences blood rheology, microvascular perfusion, and organ injury following hemorrhagic shock resuscitation. Methods: Human hemoglobin (hHb; 64.5 kDa) and four PolyhHb formulations (1078–1569 kDa) were evaluated using flow-sweep rheology, oscillatory shear analysis, red blood cell aggregation, and Quemada modeling. Male Golden Syrian hamsters subjected to 50% blood-volume hemorrhage were randomly assigned to resuscitation with hHb or one of four PolyhHb formulations, followed by systemic, microvascular, and organ-injury assessment for 60 min. Findings: Increasing PolyhHb molecular size reduced blood storage and complex moduli but increased red blood cell aggregation. PolyhHb-12 (1200 kDa) provided the most favorable microvascular recovery, with significantly greater flow in arterioles >60 µm at 60 min than PolyhHb-10 (P<0.001), PolyhHb-15 (P<0.01), and PolyhHb-16 (P<0.0001). Compared with PolyhHb-16, the absolute difference was 2.98 nL/s (95% CI 1.47–4.48). Functional capillary density did not significantly differ among treatment groups. All PolyhHb formulations produced lower renal, cardiac, hepatic, hemolytic, and inflammatory injury biomarkers than hHb. Interpretation: PolyhHb molecular size determines a trade-off between hemorheological behavior, microvascular transport, and tissue compatibility. An intermediate molecular size provided the most favorable balance between microvascular recovery and organ protection, supporting molecular size as a critical design parameter for next-generation HBOCs.
- 9 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMolecular Size-Dependent Effects of Polymerized Hemoglobin on Blood Rheology and Microvascular Perfusion
Background: Hemoglobin-based oxygen carriers (HBOCs) could provide an alternative to blood transfusion when donor blood is unavailable, but clinical translation has been limited by vasoactivity and impaired microvascular perfusion. We investigated how polymerized hemoglobin (PolyhHb) molecular size influences blood rheology, microvascular perfusion, and organ injury following hemorrhagic shock resuscitation. Methods: Human hemoglobin (hHb; 64.5 kDa) and four PolyhHb formulations (1078–1569 kDa) were evaluated using flow-sweep rheology, oscillatory shear analysis, red blood cell aggregation, and Quemada modeling. Male Golden Syrian hamsters subjected to 50% blood-volume hemorrhage were randomly assigned to resuscitation with hHb or one of four PolyhHb formulations, followed by systemic, microvascular, and organ-injury assessment for 60 min. Findings: Increasing PolyhHb molecular size reduced blood storage and complex moduli but increased red blood cell aggregation. PolyhHb-12 (1200 kDa) provided the most favorable microvascular recovery, with significantly greater flow in arterioles >60 µm at 60 min than PolyhHb-10 (P<0.001), PolyhHb-15 (P<0.01), and PolyhHb-16 (P<0.0001). Compared with PolyhHb-16, the absolute difference was 2.98 nL/s (95% CI 1.47–4.48). Functional capillary density did not significantly differ among treatment groups. All PolyhHb formulations produced lower renal, cardiac, hepatic, hemolytic, and inflammatory injury biomarkers than hHb. Interpretation: PolyhHb molecular size determines a trade-off between hemorheological behavior, microvascular transport, and tissue compatibility. An intermediate molecular size provided the most favorable balance between microvascular recovery and organ protection, supporting molecular size as a critical design parameter for next-generation HBOCs.
- Open Access
- 18 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Sex differences in cardiorenal protection by the apohemoglobin-haptoglobin complex in mice
- 18 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Open AccessSex differences in cardiorenal protection by the apohemoglobin-haptoglobin complex in mice
- 24 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (16) , 7582-7593
Optimizing the Hemoglobin-Based Oxygen Carrier Molecular Size to Balance Vascular Function and Hemodynamic Responses after Transfusion
Hemorrhagic shock remains a leading cause of mortality due to impaired oxygen delivery following severe blood loss. Hemoglobin-based oxygen carriers (HBOCs) are promising alternatives to red blood cell transfusion; however, their molecular size critically governs nitric oxide (NO) scavenging, vascular reactivity, and overall safety. Here, we systematically evaluated acellular human hemoglobin (hHb) and four polymerized hemoglobin formulations with progressively increasing molecular weights (PolyhHb-10, ∼1080 kDa; PolyhHb-12, ∼1200 kDa; PolyhHb-15, ∼1490 kDa; and PolyhHb-16, ∼1570 kDa) to define size-dependent determinants of vascular function. Ex vivo, isolated mesenteric arterioles from New Zealand white rabbits were perfused with HBOC−whole blood mixtures (1:0, 1:1, and 1:3) across physiologically relevant flow rates to quantify shear-mediated vasodilation and endothelial function. The acetylcholine challenge was used to probe NO bioavailability. In vivo validation was performed in Golden Syrian hamsters using a dorsal window chamber model to assess microvascular hemodynamics, including the vessel diameter, blood flow, and functional capillary density. PolyhHb-12 consistently preserved endothelial-dependent vasodilation and exhibited minimal NO scavenging across conditions. In contrast, larger polymers (PolyhHb-15 and PolyhHb-16) showed paradoxically increased NO scavenging despite improved capillary perfusion, indicating a trade-off between microcirculatory flow enhancement and endothelial signaling. In vivo, increasing the molecular size yielded diminishing returns in overall hemodynamic stability. Together, these findings identify an intermediate molecular size as optimal for balancing rheological properties, NO bioavailability, and vascular function. PolyhHb-12 emerges as a lead candidate, supporting the design of next-generation HBOCs with improved safety and efficacy for hemorrhagic shock resuscitation.
- 24 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (16) , 7582-7593
Optimizing the Hemoglobin-Based Oxygen Carrier Molecular Size to Balance Vascular Function and Hemodynamic Responses after Transfusion
Hemorrhagic shock remains a leading cause of mortality due to impaired oxygen delivery following severe blood loss. Hemoglobin-based oxygen carriers (HBOCs) are promising alternatives to red blood cell transfusion; however, their molecular size critically governs nitric oxide (NO) scavenging, vascular reactivity, and overall safety. Here, we systematically evaluated acellular human hemoglobin (hHb) and four polymerized hemoglobin formulations with progressively increasing molecular weights (PolyhHb-10, ∼1080 kDa; PolyhHb-12, ∼1200 kDa; PolyhHb-15, ∼1490 kDa; and PolyhHb-16, ∼1570 kDa) to define size-dependent determinants of vascular function. Ex vivo, isolated mesenteric arterioles from New Zealand white rabbits were perfused with HBOC−whole blood mixtures (1:0, 1:1, and 1:3) across physiologically relevant flow rates to quantify shear-mediated vasodilation and endothelial function. The acetylcholine challenge was used to probe NO bioavailability. In vivo validation was performed in Golden Syrian hamsters using a dorsal window chamber model to assess microvascular hemodynamics, including the vessel diameter, blood flow, and functional capillary density. PolyhHb-12 consistently preserved endothelial-dependent vasodilation and exhibited minimal NO scavenging across conditions. In contrast, larger polymers (PolyhHb-15 and PolyhHb-16) showed paradoxically increased NO scavenging despite improved capillary perfusion, indicating a trade-off between microcirculatory flow enhancement and endothelial signaling. In vivo, increasing the molecular size yielded diminishing returns in overall hemodynamic stability. Together, these findings identify an intermediate molecular size as optimal for balancing rheological properties, NO bioavailability, and vascular function. PolyhHb-12 emerges as a lead candidate, supporting the design of next-generation HBOCs with improved safety and efficacy for hemorrhagic shock resuscitation.
- Open Access
- 1 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 3154-3164
Apohemoglobin-haptoglobin complex is a therapeutic against vaso-occlusive crisis: scavenging of hemoglobin and heme
Sickle cell disease (SCD) leads to vaso-occlusive episodes (VOEs) releasing cell-free hemoglobin (Hb) and heme that drive oxidative stress, inflammation, and microvascular dysfunction. Current treatments for VOEs remain limited with no targeted therapies addressing these hemolytic byproducts. This study investigated the potential of an apohemoglobin-haptoglobin (ApoHb-Hp) complex (protein scavenger of both Hb and heme) vs Hp (scavenger of only Hb), in transgenic SCD mice exposed to hypoxia-reoxygenation. Briefly, HbSS-Townes mice instrumented with a dorsal skinfold window chamber received ApoHb-Hp (150 mg/kg), Hp alone (150 mg/kg), or an equal volume of saline vehicle, and groups were compared with HbAA controls. At the same dose, ApoHb-Hp had reduced Hb-binding capacity compared with Hp alone, but it possessed heme-binding capacity from the associated ApoHb moiety. Despite the reduced Hb-binding capacity, ApoHb-Hp produced significantly greater protective effects than Hp alone. During hypoxia, ApoHb-Hp preserved >90% of baseline arteriolar and venular flow, whereas untreated and Hp-treated mice exhibited >50% reductions. Functional capillary density at 72 hours post-hypoxia declined by 80% in untreated mice and 44% in Hp-treated mice, but only 27% in ApoHb-Hp–treated mice. Pulmonary inflammation was significantly lower in ApoHb-Hp–treated mice compared with Hp-treated mice, with reduced numbers of macrophages (15 ± 2 vs 18 ± 3), neutrophils (5 ± 1 vs 7 ± 1), and lymphocytes (18 ± 4 vs 20 ± 3). The increased effectiveness of ApoHb-Hp is due to its unique dual-scavenging mechanism. This addresses both Hb and heme toxicity, which each contribute to the pathophysiology of SCD. These findings indicate that the ApoHb-Hp complex is a promising therapeutic option for SCD.
- 1 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 3154-3164
Open AccessApohemoglobin-haptoglobin complex is a therapeutic against vaso-occlusive crisis: scavenging of hemoglobin and heme
Sickle cell disease (SCD) leads to vaso-occlusive episodes (VOEs) releasing cell-free hemoglobin (Hb) and heme that drive oxidative stress, inflammation, and microvascular dysfunction. Current treatments for VOEs remain limited with no targeted therapies addressing these hemolytic byproducts. This study investigated the potential of an apohemoglobin-haptoglobin (ApoHb-Hp) complex (protein scavenger of both Hb and heme) vs Hp (scavenger of only Hb), in transgenic SCD mice exposed to hypoxia-reoxygenation. Briefly, HbSS-Townes mice instrumented with a dorsal skinfold window chamber received ApoHb-Hp (150 mg/kg), Hp alone (150 mg/kg), or an equal volume of saline vehicle, and groups were compared with HbAA controls. At the same dose, ApoHb-Hp had reduced Hb-binding capacity compared with Hp alone, but it possessed heme-binding capacity from the associated ApoHb moiety. Despite the reduced Hb-binding capacity, ApoHb-Hp produced significantly greater protective effects than Hp alone. During hypoxia, ApoHb-Hp preserved >90% of baseline arteriolar and venular flow, whereas untreated and Hp-treated mice exhibited >50% reductions. Functional capillary density at 72 hours post-hypoxia declined by 80% in untreated mice and 44% in Hp-treated mice, but only 27% in ApoHb-Hp–treated mice. Pulmonary inflammation was significantly lower in ApoHb-Hp–treated mice compared with Hp-treated mice, with reduced numbers of macrophages (15 ± 2 vs 18 ± 3), neutrophils (5 ± 1 vs 7 ± 1), and lymphocytes (18 ± 4 vs 20 ± 3). The increased effectiveness of ApoHb-Hp is due to its unique dual-scavenging mechanism. This addresses both Hb and heme toxicity, which each contribute to the pathophysiology of SCD. These findings indicate that the ApoHb-Hp complex is a promising therapeutic option for SCD.
- Open Access
- 27 April 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119439
Sex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
- 27 April 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119439
Open AccessSex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
- Open Access
- 11 April 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Intermittent Hypoxia Associated with Sleep Apnea Disrupts Microvascular Hemodynamics and Oxygen Delivery
Obstructive sleep apnea (OSA) is characterized by recurrent episodes of intermittent hypoxia (IH). In this study, we investigated how cyclic IH (21%/10% O₂) acutely alters systemic hemodynamics and microvascular vascular tone, hemodynamics, and oxygen transport compared to the control (21%/21% O₂). Using a dorsal window chamber model on unanesthetized Golden Syrian hamsters, we applied 30-second oxygen cycling for 60 minutes. Microvascular oxygen saturation was continuously monitored using hyperspectral imaging (HSI), and vessel diameter, red blood cell velocity, functional capillary density (FCD), and vascular resistance were quantified through intravital microscopy. Animals exposed to IH exhibited significant reductions in mean arterial pressure and arterial oxygen saturation, along with increased heart rate and blood lactate. Microvascular SO₂ declined rapidly in the microcirculation and stabilized after 8 mins. Arteriolar blood flow decreased, and FCD was significantly reduced relative to both baseline and control. Despite a decrease in vascular resistance, vasodilatory compensation was insufficient and resulted in decreased oxygen delivery (DO₂) and oxygen extraction (VO₂) to tissues. The oxygen extraction ratio increased, suggesting a limited capacity to offset hypoxic stress. These findings demonstrate that cyclic IH significantly disrupts peripheral microcirculatory flow and oxygenation, highlighting the relevance of IH models in assessing oxygen transport during OSA.
- 11 April 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessIntermittent Hypoxia Associated with Sleep Apnea Disrupts Microvascular Hemodynamics and Oxygen Delivery
Obstructive sleep apnea (OSA) is characterized by recurrent episodes of intermittent hypoxia (IH). In this study, we investigated how cyclic IH (21%/10% O₂) acutely alters systemic hemodynamics and microvascular vascular tone, hemodynamics, and oxygen transport compared to the control (21%/21% O₂). Using a dorsal window chamber model on unanesthetized Golden Syrian hamsters, we applied 30-second oxygen cycling for 60 minutes. Microvascular oxygen saturation was continuously monitored using hyperspectral imaging (HSI), and vessel diameter, red blood cell velocity, functional capillary density (FCD), and vascular resistance were quantified through intravital microscopy. Animals exposed to IH exhibited significant reductions in mean arterial pressure and arterial oxygen saturation, along with increased heart rate and blood lactate. Microvascular SO₂ declined rapidly in the microcirculation and stabilized after 8 mins. Arteriolar blood flow decreased, and FCD was significantly reduced relative to both baseline and control. Despite a decrease in vascular resistance, vasodilatory compensation was insufficient and resulted in decreased oxygen delivery (DO₂) and oxygen extraction (VO₂) to tissues. The oxygen extraction ratio increased, suggesting a limited capacity to offset hypoxic stress. These findings demonstrate that cyclic IH significantly disrupts peripheral microcirculatory flow and oxygenation, highlighting the relevance of IH models in assessing oxygen transport during OSA.
- 4 March 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Acellular Hemoglobin Impairs Cardiomyocyte Excitation-Contraction Coupling
Heart failure is a significant complication of chronic intravascular hemolysis, a condition characterized by red blood cells (RBCs) breakdown, leading to the release of acellular hemoglobin (Hb) and its oxidized form, methemoglobin (MetHb), into the bloodstream. Acellular Hb promotes nitric oxide (NO) scavenging, oxidative stress, inflammation, iron overload, and functional tissue impairment. This study investigates the direct impact of Hb and MetHb on cardiomyocyte function by assessing calcium transients, fractional shortening, and reactive oxygen species (ROS) formation. The study also evaluated the effects of polymerized Hb, NO scavenging, and antioxidant therapy using N-acetylcysteine (NAC) on cardiomyocyte contractility. Our results show that acellular Hb and MetHb impair cardiomyocyte function by prolonging calcium transient half-life, reducing contractility, and increasing ROS production. Polymerization of Hb and antioxidant supplementation offered partial protection but did not fully mitigate these effects. Inhibiting NO synthase did not increase Hb toxicity, indicating that NO scavenging is not the sole toxicity pathway. These findings demonstrate that Hb-induced cardiomyocyte dysfunction involves a multifactorial mechanism, including NO scavenging, oxidative stress, and disrupted calcium dynamics. Although Hb polymerization and antioxidants offer limited protection, novel multi-target strategies are essential to address Hb toxicity in hemolytic disorders and the use of Hb-based oxygen carriers. Export
- 4 March 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Acellular Hemoglobin Impairs Cardiomyocyte Excitation-Contraction Coupling
Heart failure is a significant complication of chronic intravascular hemolysis, a condition characterized by red blood cells (RBCs) breakdown, leading to the release of acellular hemoglobin (Hb) and its oxidized form, methemoglobin (MetHb), into the bloodstream. Acellular Hb promotes nitric oxide (NO) scavenging, oxidative stress, inflammation, iron overload, and functional tissue impairment. This study investigates the direct impact of Hb and MetHb on cardiomyocyte function by assessing calcium transients, fractional shortening, and reactive oxygen species (ROS) formation. The study also evaluated the effects of polymerized Hb, NO scavenging, and antioxidant therapy using N-acetylcysteine (NAC) on cardiomyocyte contractility. Our results show that acellular Hb and MetHb impair cardiomyocyte function by prolonging calcium transient half-life, reducing contractility, and increasing ROS production. Polymerization of Hb and antioxidant supplementation offered partial protection but did not fully mitigate these effects. Inhibiting NO synthase did not increase Hb toxicity, indicating that NO scavenging is not the sole toxicity pathway. These findings demonstrate that Hb-induced cardiomyocyte dysfunction involves a multifactorial mechanism, including NO scavenging, oxidative stress, and disrupted calcium dynamics. Although Hb polymerization and antioxidants offer limited protection, novel multi-target strategies are essential to address Hb toxicity in hemolytic disorders and the use of Hb-based oxygen carriers. Export
- Open Access
- 15 August 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 191, 118461
Sex-specific glomerular filtration rate changes in response to acute hemoglobin exposure
- 15 August 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 191, 118461
Open AccessSex-specific glomerular filtration rate changes in response to acute hemoglobin exposure
- Open Access
- 23 June 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 65 (2) , 294-308
Resuscitation from Hemorrhagic Shock with a Novel Protein Cocktail Restores Microvascular Perfusion and Protects Vital Organs
Introduction: Low-titer O positive whole blood (LTOWB) has been introduced in prehospital care to resuscitate patients; however, the logistical obstacles, cost of carrying LTOWB, and the availability of it in trauma situations are a point of concern. Therefore, fluids, like lactated Ringer’s (LR) and hydroxyethyl starch (HES), have been considered alternatives to LTOWB transfusion. Unfortunately, they dilute plasma proteins in the circulation and have unfavorable side effects. This study presents an alternative, a protein cocktail (PC). The PC combines human serum albumin, transferrin, haptoglobin, and hemopexin. This study compares the ability to resuscitate from hemorrhagic shock (HS) with whole blood (WB), LR, 6% HES, and PC. Methods: Unanesthetized golden Syrian hamsters instrumented with the dorsal window chambers were subjected to hemorrhage (50% blood volume), followed by 30 min hypovolemic shock, and resuscitated with 50% shed volume. The outcome was evaluated through systemic parameters, blood gases, microcirculatory hemodynamics, oxygen tension and saturation, metabolomics, and markers of organ injury/function. Additionally, to investigate the impact of the experimental solutions on the coagulation cascade, Sprague-Dawley rats were subjected to an isovolemic exchange infusion of 20% of the animal’s blood volume. Results: The PC showed favorable outcomes, restoring microvasculature hemodynamics comparable to resuscitation with WB and superior to LR and HES. PC reduced acute inflammation, positively impacted organ function markers, and restored metabolomic homeostasis without coagulopathies observed with HES. Conclusion: In conclusion, the PC shows some promise as a resuscitation from HS when WB is not available and superior to classic crystalloids and colloids (LR and HES). Further studies with the PC are needed to ensure its efficacy and safety in other experimental models.
- 23 June 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 65 (2) , 294-308
Open AccessResuscitation from Hemorrhagic Shock with a Novel Protein Cocktail Restores Microvascular Perfusion and Protects Vital Organs
Introduction: Low-titer O positive whole blood (LTOWB) has been introduced in prehospital care to resuscitate patients; however, the logistical obstacles, cost of carrying LTOWB, and the availability of it in trauma situations are a point of concern. Therefore, fluids, like lactated Ringer’s (LR) and hydroxyethyl starch (HES), have been considered alternatives to LTOWB transfusion. Unfortunately, they dilute plasma proteins in the circulation and have unfavorable side effects. This study presents an alternative, a protein cocktail (PC). The PC combines human serum albumin, transferrin, haptoglobin, and hemopexin. This study compares the ability to resuscitate from hemorrhagic shock (HS) with whole blood (WB), LR, 6% HES, and PC. Methods: Unanesthetized golden Syrian hamsters instrumented with the dorsal window chambers were subjected to hemorrhage (50% blood volume), followed by 30 min hypovolemic shock, and resuscitated with 50% shed volume. The outcome was evaluated through systemic parameters, blood gases, microcirculatory hemodynamics, oxygen tension and saturation, metabolomics, and markers of organ injury/function. Additionally, to investigate the impact of the experimental solutions on the coagulation cascade, Sprague-Dawley rats were subjected to an isovolemic exchange infusion of 20% of the animal’s blood volume. Results: The PC showed favorable outcomes, restoring microvasculature hemodynamics comparable to resuscitation with WB and superior to LR and HES. PC reduced acute inflammation, positively impacted organ function markers, and restored metabolomic homeostasis without coagulopathies observed with HES. Conclusion: In conclusion, the PC shows some promise as a resuscitation from HS when WB is not available and superior to classic crystalloids and colloids (LR and HES). Further studies with the PC are needed to ensure its efficacy and safety in other experimental models.
- Open Access
- 22 November 2024
- Published by Wiley in Physiological Reports
- Vol. 12 (22) , e70132
Mitigating hemoglobin‐induced nephropathy: ApoHb‐hp protection of podocytes
This study investigates hemoglobin (Hb)‐induced kidney injury and the protective role of the ApoHemoglobin‐Haptoglobin (ApoHb‐Hp) complex against heme and Hb damage. Hb facilitates oxygen (O2) delivery but poses challenges outside red blood cells (RBCs) due to toxic Hb and heme mechanisms. These are managed by binding to serum proteins like Haptoglobin (Hp) and Hemopexin (Hpx). During hemolysis, depletion of Hp and Hpx leaves tissues vulnerable to Hb and heme. To address this, we developed the ApoHb‐Hp complex, based on Apohemoglobin, which is produced by removing heme from Hb, conjugated with Hp. This complex acts as a dual scavenger for Hb and heme, preventing tissue damage. Our findings demonstrate that ApoHb‐Hp significantly protects MPC5 podocytes from Hb‐induced damage. Fluorescent staining showed a higher percentage of nephrin‐positive cells in the ApoHb‐Hp group, and MTT assays revealed enhanced cell viability compared to Hb alone. Additionally, ApoHb‐Hp reduced reactive oxygen species (ROS) production, with the Hb group exhibiting significantly elevated ROS levels. The ApoHb‐Hp complex mitigated the depletion of protective mechanisms, as shown by significant increases in superoxide dismutase (SOD) and glutathione (GSH). Moreover, ApoHb‐Hp treatment reduced the activation of the NLRP3 inflammasome signaling pathway and inflammatory cytokines IL‐1β and IL‐18. These findings underscore the therapeutic potential of ApoHb‐Hp in mitigating Hb‐induced renal damage by preserving podocyte viability and reducing oxidative stress. Overall, ApoHb‐Hp maintained protective mechanisms depleted otherwise by Hb. These findings highlight ApoHb‐Hp's potential as a therapeutic agent against Hb‐induced renal damage, offering insights into its mechanisms and implications for treating conditions involving hemolysis.
- 22 November 2024
- Published by Wiley in Physiological Reports
- Vol. 12 (22) , e70132
Open AccessMitigating hemoglobin‐induced nephropathy: ApoHb‐hp protection of podocytes
This study investigates hemoglobin (Hb)‐induced kidney injury and the protective role of the ApoHemoglobin‐Haptoglobin (ApoHb‐Hp) complex against heme and Hb damage. Hb facilitates oxygen (O2) delivery but poses challenges outside red blood cells (RBCs) due to toxic Hb and heme mechanisms. These are managed by binding to serum proteins like Haptoglobin (Hp) and Hemopexin (Hpx). During hemolysis, depletion of Hp and Hpx leaves tissues vulnerable to Hb and heme. To address this, we developed the ApoHb‐Hp complex, based on Apohemoglobin, which is produced by removing heme from Hb, conjugated with Hp. This complex acts as a dual scavenger for Hb and heme, preventing tissue damage. Our findings demonstrate that ApoHb‐Hp significantly protects MPC5 podocytes from Hb‐induced damage. Fluorescent staining showed a higher percentage of nephrin‐positive cells in the ApoHb‐Hp group, and MTT assays revealed enhanced cell viability compared to Hb alone. Additionally, ApoHb‐Hp reduced reactive oxygen species (ROS) production, with the Hb group exhibiting significantly elevated ROS levels. The ApoHb‐Hp complex mitigated the depletion of protective mechanisms, as shown by significant increases in superoxide dismutase (SOD) and glutathione (GSH). Moreover, ApoHb‐Hp treatment reduced the activation of the NLRP3 inflammasome signaling pathway and inflammatory cytokines IL‐1β and IL‐18. These findings underscore the therapeutic potential of ApoHb‐Hp in mitigating Hb‐induced renal damage by preserving podocyte viability and reducing oxidative stress. Overall, ApoHb‐Hp maintained protective mechanisms depleted otherwise by Hb. These findings highlight ApoHb‐Hp's potential as a therapeutic agent against Hb‐induced renal damage, offering insights into its mechanisms and implications for treating conditions involving hemolysis.